Stockscreener 앱 받기
8.96
1.43%
-0.13
시장 영업 전:
9.09
0.13
+1.45%
Biohaven Ltd 주식(BHVN)의 최신 뉴스
Biohaven completes enrollment in obesity drug trial By Investing.com - Investing.com Australia
Biohaven (NASDAQ: BHVN) director reports gifting 34,684 shares, adds family trust - Stock Titan
Biohaven shares edge higher after completing enrollment in obesity drug trial - MSN
Risk Off: What is the long term forecast for Biohaven Ltd stock2026 Market WrapUp & Precise Swing Trade Alerts - baoquankhu1.vn
Biohaven Therapeutics discloses prodrugs of betahistine - BioWorld MedTech
Biohaven Ltd. Completes Enrollment In Phase 2 Obesity Study With Taldefgrobep Alfa - marketscreener.com
Biohaven completes enrollment in obesity drug trial - Investing.com
Biohaven stock rises as obesity trial completes enrollment - Investing.com
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment - PR Newswire
Biohaven has completed enrollment for its obesity study—However, the market still hasn't factored in the potential risk of the trial not succeeding - Bitget
Precision Trading with Biohaven Ltd. (BHVN) Risk Zones - Stock Traders Daily
Pullback Watch: Is Biohaven Ltd on track to beat earnings2026 EndofMonth & High Win Rate Trade Alerts - baoquankhu1.vn
Valuation Update: What are analysts price targets for Biohaven LtdMarket Sentiment Review & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Biohaven Ltd. ($BHVN) CEO 2025 Pay Revealed - Quiver Quantitative
Integral Health Asset Management LLC Buys 350,000 Shares of Biohaven Ltd. $BHVN - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Allogene Therapeutics (ALLO) - The Globe and Mail
Biohaven (NYSE: BHVN) outlines R&D pipeline and 2026 shareholder votes - Stock Titan
Capital Research Global Investors Raises Position in Biohaven Ltd. $BHVN - MarketBeat
Macro Review: Is Biohaven Ltd gaining market shareWeekly Trading Summary & Technical Entry and Exit Tips - baoquankhu1.vn
TD Cowen Boosts Biohaven (NYSE:BHVN) Price Target to $30.00 - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Dyne Therapeutics (DYN), Biohaven Ltd. (BHVN) and Teladoc (TDOC) - The Globe and Mail
Assessing Biohaven (BHVN) Valuation After Pipeline Optimism And Supportive Sector Sentiment - simplywall.st
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why Biohaven (BHVN) Is Down 13.5% After Narrower Losses And A New Share Shelf Registration - simplywall.st
Raymond James Maintains Strong Buy on Biohaven Ltd. (BHVN) March 2026 - Meyka
Biohaven (BHVN) director trust purchase corrected to 28,400 shares - Stock Titan
Raymond James reiterates Strong Buy on Biohaven stock after competitor data - Investing.com Australia
Raymond James reiterates Strong Buy on Biohaven stock after competitor data By Investing.com - Investing.com South Africa
Biohaven Reports Q4 EPS Beat Expectations, Plans Stock Issuance - Intellectia AI
Biohaven (NYSE:BHVN) Shares Gap UpTime to Buy? - MarketBeat
Biohaven Ltd stock whipsaws after FDA exit revives rare-disease bets - Bez Kabli
What's Going On With Biohaven Stock On Monday? - Benzinga
Breakout Watch: Can Biohaven Ltd stock outperform in a bear marketJuly 2025 PostEarnings & Risk Managed Trade Strategies - baoquankhu1.vn
Death Cross: Is Biohaven Ltd a stock for growth or value investors2025 Winners & Losers & Reliable Trade Execution Plans - baoquankhu1.vn
Technical Reactions to BHVN Trends in Macro Strategies - Stock Traders Daily
TD Asset Management Inc Cuts Stake in Biohaven Ltd. $BHVN - MarketBeat
Biohaven stock price target lowered to $10 by H.C. Wainwright - Investing.com South Africa
Biohaven (NYSE:BHVN) Given New $10.00 Price Target at HC Wainwright - MarketBeat
BHVN Earnings History & Surprises | EPS & Revenue Results | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
BHVN: HC Wainwright & Co. Lowers Price Target While Maintaining - GuruFocus
Assessing Biohaven (BHVN) Valuation After Recent Share Price Volatility - simplywall.st
Biohaven Reshapes Pipeline And Funding As Late Stage Trials Approach - Yahoo Finance
Biohaven (BHVN) VP and CAO awarded 50,000 stock options with 4-year vesting - Stock Titan
Biohaven (BHVN) CFO awarded 175,000 stock options in Form 4 filing - Stock Titan
Biohaven Ltd. (BHVN) SVP awarded 175,000 stock options with 4-year vesting - Stock Titan
Biohaven (BHVN) Chief Scientific Officer awarded 175,000 stock options - Stock Titan
Biohaven (BHVN) CEO Vlad Coric granted 550,000 stock options - Stock Titan
Key facts: Biohaven posts $738.8M loss; opakalim shows promise in study; analysts give 'buy' rating - TradingView
Biohaven (NYSE:BHVN) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Piper Sandler reiterates Biohaven stock rating on 2026 catalysts By Investing.com - Investing.com Canada
Piper Sandler reiterates Biohaven stock rating on 2026 catalysts - Investing.com Nigeria
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 77% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Biohaven reduces scope of R&D cuts as pipeline progresses - Fierce Biotech
RBC Raises Price Target on Biohaven to $23 From $22, Keeps Outperform, Speculative Risk - marketscreener.com
JPMorgan Chase & Co. Reduces Stake in Biohaven Ltd. $BHVN - MarketBeat
Biohaven Ltd. Common Shares (NY: BHVN - The Chronicle-Journal
Biohaven Ltd reports results for the quarter ended September 30Earnings Summary - TradingView
Biohaven (NYSE:BHVN) Announces Earnings Results - MarketBeat
Biohaven (NYSE: BHVN) refocuses pipeline after key trial and FDA setbacks - Stock Titan
Biohaven 10-K: $0 Revenue, $(0.74)B Net Loss; Cash ~$319M - TradingView
Earnings Flash (BHVN) Biohaven Ltd. Posts Q4 Adjusted Loss $0.90 per Share, vs. FactSet Est of $-0.87 - marketscreener.com
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results - PR Newswire
How US$600 Million Non-Dilutive Funding and R&D Cuts Will Impact Biohaven (BHVN) Investors - simplywall.st
Biohaven Ltd. (BHVN): A Bull Case Theory - Yahoo Finance
BHVN Should I Buy - Intellectia AI
Assessing Biohaven (BHVN) Valuation After A Sharp One Year Decline And Recent Three Month Rebound - simplywall.st
1.20%
0.06%
자본화:
|
볼륨(24시간):